Aspirin promotes bone marrow mesenchymal stem cell-based calvarial bone regeneration in mini swine

Stem Cell Research & Therapy

Yi Liu²  Songlin Wang⁴  Zhigang Zhao¹  Fu Wang⁴  Shenghui Mei¹  Jimin Xiong²  Yu Cao³ 

[1] Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, Beijing, P. R. China;Laboratory of Tissue Regeneration and Immunology and Department of Periodontics, Beijing Key Laboratory of Tooth Regeneration and Function Reconstruction, School of Stomatology, Capital Medical University, Tian Tan Xi Li No.4, Beijing 100050, P. R. China;Department of General Dentistry, School of Stomatology, Capital Medical University, Beijing, P. R. China;Molecular Laboratory for Gene Therapy and Tooth Regeneration, Beijing Key Laboratory of Tooth Regeneration and Function Reconstruction, School of Stomatology, Capital Medical University, Beijing, P. R. China

关键词: Mini swine;    Bone regeneration;    Aspirin;    Mesenchymal stem cells;   

Others  :  1234415
DOI  :  10.1186/s13287-015-0200-4

 received in 2015-03-11, accepted in 2015-10-08,  发布年份 2015

【 摘 要 】

Introduction

Stem cells have great therapeutic potential due to their capacity for self-renewal and their potential for differentiating into multiple cell lineages. It has been recently shown that the host immune system has fundamental effects on the fate of transplanted mesenchymal stem cells during bone repair, where the topical administration of aspirin is capable of improving calvarial bone repair in rodents by inhibiting tumor necrosis factor-α (TNF-α) and interferon-γ (IFN-γ) production. This study investigates whether aspirin is capable of accelerating the regenerative potential of bone marrow mesenchymal stem cells (BMSC) in a mini swine calvarial bone defect model.

Methods

Calvarial bone defects (3 cm × 1.8 cm oval defect) in mini swine were treated with BMSC pretreated with 75 μg/ml aspirin for 24 h seeded onto hydroxyaptite/tricalcium phosphatel (HA/TCP), or with BMSC with HA/TCP, or with HA/TCP only, or remained untreated. Animals were scanned with micro-computed tomography (microCT) at 2 days and 6 months postsurgery and were sacrificed at 6 months postsurgery with decalcified tissues being processed for histomorphometric examination. The cytokine levels, including TNF-α and IFN-γ, were measured by enzyme-linked immunosorbent assay (ELISA).

Results

Aspirin at 75 μg/ml promoted the osteogenesis of BMSC in vitro and in vivo, shown by Alizarin Red staining and new bone volume in the nude mice transplantation model (p < 0.01), respectively. Defects treated with aspirin-BMSC showed significantly greater new bone fill compared with other three groups at 6 months postsurgery (p < 0.01). Aspirin-BMSC treatment has significantly decreased the concentration of TNF-α and IFN-γ (p < 0.05).

Conclusions

The present study shows that BMSC pretreated with aspirin have a greater capacity to repair calvarial bone defects in a mini swine model. The results suggest that the administration of aspirin is capable of improving BMSC-mediated calvarial bone regeneration in a big animal model.

【 授权许可】

   
2015 Cao et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

Fig. 4.

Fig. 5.

Fig. 6.

Fig. 1.

Fig. 2.

Fig. 3.

Fig. 4.

Fig. 5.

Fig. 6.

【 参考文献 】

• [1]Bianco P, Riminucci M, Gronthos S, Robey PG: Bone marrow stromal stem cells: nature, biology, and potential applications. Stem Cells. 2001, 19:180-92.
• [2]Friedenstein AJ, Chailakhyan RK, Latsinik NV, Panasyuk AF, Keiliss-Borok IV: Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo. Transplantation 1974, 17:331-40.
• [3]Owen M, Friedenstein AJ: Stromal stem cells: marrow-derived osteogenic precursors. Ciba Found Symp. 1988, 136:42-60.
• [4]Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al.: Multilineage potential of adult human mesenchymal stem cells. Science. 1999, 284:143-7.
• [5]Prockop DJ: Marrow stromal cells as stem cells for nonhematopoietic tissues. Science. 1997, 276:71-4.
• [6]Caplan AI: Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. J Cell Physiol. 2007, 213:341-7.
• [7]García-Gómez I, Elvira G, Zapata AG, Lamana ML, Ramírez M, Castro JG, et al.: Mesenchymal stem cells: biological properties and clinical applications. Expert Opin Biol Ther. 2010, 10:1453-68.
• [8]Tasso R, Fais F, Reverberi D, Tortelli F, Cancedda R: The recruitment of two consecutive and different waves of host stem/progenitor cells during the development of tissue-engineered bone in a murine model. Biomaterials. 2010, 31:2121-9.
• [9]Bueno EM, Glowacki J: Cell-free and cell-based approaches for bone regeneration. Nat Rev Rheumatol. 2009, 5:685-97.
• [10]Le Blanc K, Tammik C, Rosendahl K, Zetterberg E, Ringdén O: HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol. 2003, 31:890-6.
• [11]Zhang B, Liu R, Shi D, Liu X, Chen Y, Dou X, et al.: Mesenchymal stem cells induce mature dendritic cells into a novel Jagged-2-dependent regulatory dendritic cell population. Blood. 2009, 113:46-57.
• [12]Majumdar MK, Keane-Moore M, Buyaner D, Hardy WB, Moorman MA, McIntosh KR, et al.: Characterization and functionality of cell surface molecules on human mesenchymal stem cells. J Biomed Sci. 2003, 10:228-41.
• [13]Liu Y, Wang L, Kikuiri T, Akiyama K, Chen C, Xu X, et al.: Mesenchymal stem cell-based tissue regeneration is governed by recipient T lymphocytes via IFN-γ and TNF-α. Nat Med. 2011, 17:1594-601.
• [14]Su Y, Shi S, Liu Y: Immunomodulation regulates mesenchymal stem cell-based bone regeneration. Oral Dis. 2014, 20:633-6.
• [15]Shi Y, Wei L, Wang Y, Ren G: Stem cells deployed for bone repair hijacked by T cells. Cell Stem Cell. 2012, 10:6-8.
• [16]Yamaza T, Miura Y, Bi Y, Liu Y, Akiyama K, Sonoyama W, et al.: Pharmacologic stem cell based intervention as a new approach to osteoporosis treatment in rodents. PLoS One. 2008, 3:e2615.
• [17]Gronthos S, Zannettino AC, Hay SJ, Shi S, Graves SE, Kortesidis A, et al.: Molecular and cellular characterisation of highly purified stromal stem cells derived from human bone marrow. J Cell Sci. 2003, 116:1827-35.
• [18]Xiong J, Mrozik KM, Gronthos S, Bartold PM: Epithelial cell rests of Malassez contain unique stem cell populations capable of undergoing epithelial-mesenchymal transition. Stem Cells Dev. 2012, 21:2012-25.
• [19]Jonsdottir-Buch SM, Lieder R, Sigurjonsson OE: Platelet lysates produced from expired platelet concentrates support growth and osteogenic differentiation of mesenchymal stem cells. PLoS One. 2013, 8:e68984.
• [20]Fan Z, Yamaza T, Lee JS, Yu J, Wang SL, Fan G, et al.: BCOR regulates mesenchymal stem cell function by epigenetic mechanisms. Nat Cell Biol. 2009, 11:1002-9.
• [21]Fang D, Seo BM, Liu Y, Sonoyama W, Yamaza T, Zhang C, et al.: Transplantation of mesenchymal stem cells is an optimal approach for plastic surgery. Stem Cells. 2007, 25:1021-8.
• [22]Wang S, Liu Y, Fang D, Shi S: The miniature pig: a useful large animal model for dental and orofacial research. Oral Dis. 2007, 13:530-7.
• [23]Carbone LD, Tylavsky FA, Cauley JA, Harris TB, Lang TF, Bauer DC, et al.: Association between bone mineral density and the use of nonsteroidal anti-inflammatory drugs and aspirin: impact of cyclooxygenase selectivity. J Bone Miner Res. 2003, 18:1795-802.
• [24]Shi S, Yamaza T, Akiyama K: Is aspirin treatment an appropriate intervention to osteoporosis? Fut Rheumatol. 2008, 3:499-502.
• [25]Lussana F, Squizzato A, Permunian ET, Cattaneo M: A systematic review on the effect of aspirin in the prevention of post-operative arterial thrombosis in patients undergoing total hip and total knee arthroplasty. Thromb Res. 2014, 134:599-603.
• [26]Chen C, Akiyama K, Yamaza T, You YO, Xu X, Li B, et al.: Telomerase governs immunomodulatory properties of mesenchymal stem cells by regulating FAS ligand expression. EMBO Mol Med. 2014, 6:322-34.
• [27]Shi S, Gronthos S, Chen S, Reddi A, Counter CM, Robey PG, et al.: Bone formation by human postnatal bone marrow stromal stem cells is enhanced by telomerase expression. Nat Biotechnol. 2002, 20:587-91.
• [28]Liu D, Xu J, Liu O, Fan Z, Liu Y, Wang F, et al.: Mesenchymal stem cells derived from inflamed periodontal ligaments exhibit impaired immunomodulation. J Clin Periodontol. 2012, 39:1174-82.
• [29]Kwon MS, Shim EJ, Seo YJ, Choi SS, Lee JY, Lee HK, et al.: Effect of aspirin and acetaminophen on proinflammatory cytokine-induced pain behavior in mice. Pharmacology. 2005, 74:152-6.
• [30]Grotz W, Siebig S, Olschewski M, Strey CW, Peter K: Low-dose aspirin therapy is associated with improved allograft function and prolonged allograft survival after kidney transplantation. Transplantation. 2004, 77:1848-53.
• [31]Tang J, Xiong J, Wu T, Tang Z, Ding G, Zhang C, et al.: Aspirin treatment improved mesenchymal stem cell immunomodulatory properties via the 15d-PGJ2/PPARγ/TGF-β1 pathway. Stem Cells Dev. 2014, 23:2093-103.